Estimated dopamine D2 receptor occupancy and remission in schizophrenia: Analysis of the catie data

Sho Moriguchi, Robert R. Bies, Gary Remington, Takefumi Suzuki, David C. Mamo, Koichiro Watanabe, Masaru Mimura, Bruce G. Pollock, Hiroyuki Uchida

研究成果: Article

19 引用 (Scopus)

抄録

In treating schizophrenia, 65% to 80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3% ± 9.8% and 60.5% ± 20.2%, respectively; among these individuals, 46.7% (14 patients) did not achieve continuous blockade of 65% or greater (ie, trough D2 occupancy of <65%). In conclusion, approximately half of patients with remission did not achieve continuous blockade of estimated D2 receptor occupancy 5% or greater. These results extend our previous findings and suggest that sustained D2 receptor occupancy greater than 65% may not always be necessary for the maintenance treatment of schizophrenia.

元の言語English
ページ(範囲)682-685
ページ数4
ジャーナルJournal of Clinical Psychopharmacology
33
発行部数5
DOI
出版物ステータスPublished - 2013 10

Fingerprint

Dopamine D2 Receptors
Schizophrenia
olanzapine
Antipsychotic Agents
Clinical Trials, Phase I
Risperidone
Therapeutics
Pharmacokinetics
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Medicine(all)

これを引用

Estimated dopamine D2 receptor occupancy and remission in schizophrenia : Analysis of the catie data. / Moriguchi, Sho; Bies, Robert R.; Remington, Gary; Suzuki, Takefumi; Mamo, David C.; Watanabe, Koichiro; Mimura, Masaru; Pollock, Bruce G.; Uchida, Hiroyuki.

:: Journal of Clinical Psychopharmacology, 巻 33, 番号 5, 10.2013, p. 682-685.

研究成果: Article

Moriguchi, Sho ; Bies, Robert R. ; Remington, Gary ; Suzuki, Takefumi ; Mamo, David C. ; Watanabe, Koichiro ; Mimura, Masaru ; Pollock, Bruce G. ; Uchida, Hiroyuki. / Estimated dopamine D2 receptor occupancy and remission in schizophrenia : Analysis of the catie data. :: Journal of Clinical Psychopharmacology. 2013 ; 巻 33, 番号 5. pp. 682-685.
@article{4930b947138c44dd853e65f7a792713c,
title = "Estimated dopamine D2 receptor occupancy and remission in schizophrenia: Analysis of the catie data",
abstract = "In treating schizophrenia, 65{\%} to 80{\%} occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3{\%} ± 9.8{\%} and 60.5{\%} ± 20.2{\%}, respectively; among these individuals, 46.7{\%} (14 patients) did not achieve continuous blockade of 65{\%} or greater (ie, trough D2 occupancy of <65{\%}). In conclusion, approximately half of patients with remission did not achieve continuous blockade of estimated D2 receptor occupancy 5{\%} or greater. These results extend our previous findings and suggest that sustained D2 receptor occupancy greater than 65{\%} may not always be necessary for the maintenance treatment of schizophrenia.",
author = "Sho Moriguchi and Bies, {Robert R.} and Gary Remington and Takefumi Suzuki and Mamo, {David C.} and Koichiro Watanabe and Masaru Mimura and Pollock, {Bruce G.} and Hiroyuki Uchida",
year = "2013",
month = "10",
doi = "10.1097/JCP.0b013e3182979a0a",
language = "English",
volume = "33",
pages = "682--685",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Estimated dopamine D2 receptor occupancy and remission in schizophrenia

T2 - Analysis of the catie data

AU - Moriguchi, Sho

AU - Bies, Robert R.

AU - Remington, Gary

AU - Suzuki, Takefumi

AU - Mamo, David C.

AU - Watanabe, Koichiro

AU - Mimura, Masaru

AU - Pollock, Bruce G.

AU - Uchida, Hiroyuki

PY - 2013/10

Y1 - 2013/10

N2 - In treating schizophrenia, 65% to 80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3% ± 9.8% and 60.5% ± 20.2%, respectively; among these individuals, 46.7% (14 patients) did not achieve continuous blockade of 65% or greater (ie, trough D2 occupancy of <65%). In conclusion, approximately half of patients with remission did not achieve continuous blockade of estimated D2 receptor occupancy 5% or greater. These results extend our previous findings and suggest that sustained D2 receptor occupancy greater than 65% may not always be necessary for the maintenance treatment of schizophrenia.

AB - In treating schizophrenia, 65% to 80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms and cognitive impairments. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain clinical response. The data set from phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) trial was reappraised. Thirty patients receiving risperidone (12 patients), olanzapine (12 patients), or ziprasidone (6 patients) fulfilled the following definition of remission and were included: a score of 3 or less on the 8 specific items in the Positive and Negative Syndrome Scale (ie, P1, P2, P3, N1, N4, N6, G5, and G9; adopted from Andreasen et al, 2005) at the initial assessment and months 1, 2, and 6. Peak and trough D2 receptor occupancy levels at month 6 were estimated from plasma antipsychotic concentrations using population pharmacokinetic analysis and our D2 prediction model. Estimated mean ± SD peak and trough D2 receptor occupancy levels at month 6 were 70.3% ± 9.8% and 60.5% ± 20.2%, respectively; among these individuals, 46.7% (14 patients) did not achieve continuous blockade of 65% or greater (ie, trough D2 occupancy of <65%). In conclusion, approximately half of patients with remission did not achieve continuous blockade of estimated D2 receptor occupancy 5% or greater. These results extend our previous findings and suggest that sustained D2 receptor occupancy greater than 65% may not always be necessary for the maintenance treatment of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=84883817566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883817566&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3182979a0a

DO - 10.1097/JCP.0b013e3182979a0a

M3 - Article

C2 - 23899638

AN - SCOPUS:84883817566

VL - 33

SP - 682

EP - 685

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -